Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era

Hiroki Ishihara(Tokyo Women's Medical University), Toshio Takagi(Tokyo Women's Medical University), Hidekazu Tachibana, Hirohito Kobayashi(Ebina General Hospital), Kazuhiko Yoshida(Tokyo Women's Medical University Hospital), Tsunenori Kondo(Tokyo Women's Medical University Adachi Medical Center), Hironori Fukuda(Tokyo Women's Medical University), Yasunobu Hashimoto, Yuki Nemoto(Tokyo Women's Medical University Adachi Medical Center), Hiroaki Shimmura(Jyoban Hospital of Tokiwa Foundation), Junpei Iizuka(Tokyo Women's Medical University), Kazunari Tanabe(Shonan Kamakura General Hospital), Kazutaka Nakamura(Tokyo Women's Medical University Hospital)
Targeted Oncology
April 23, 2022
Cited by 10


Related Papers